Developing a new class of HIV drug: Biotron

Dr Michelle Miller is the CEO of Biotron which has an HIV drug. The company hit the jackpot in September with a phase two trial result that took the share price from 2 cents to 30 cents. Alan Kohler spoke to Dr Miller to find out more.

Become a TCI Community Member Now

Stay up to date and make better informed decisions.
Get access to all this exclusive content and so much more every week!

  • $1 for the first month
  • $25/month membership
  • Cancel anytime, no lock in contract
  • Access to Private Facebook group
  • Smartphone App (coming soon)